We are live on ! Find out more
TI

tru Independence Portfolio holdings

AUM $202M
1-Year Est. Return 15.81%
This Fund
S&P 500
This Quarter Est. Return
+8.29%
1 Year Est. Return
+15.81%
3 Year Est. Return
+42.5%
5 Year Est. Return
+46.34%
10 Year Est. Return
AUM
$695M
AUM Growth
Cap. Flow
+$902M
Cap. Flow %
129.79%
Top 10 Hldgs %
22.88%
Holding
959
New
957
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 16.84%
2 Technology 10.24%
3 Industrials 8.78%
4 Financials 8.55%
5 Consumer Discretionary 8.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRSP
951
DELISTED
Perspecta Inc. Common Stock
PRSP
$0 ﹤0.01%
+2
New +$53
MFGP
952
DELISTED
Micro Focus International plc. American Depositary Shares, each representing One Ordinary Share
MFGP
$0 ﹤0.01%
+7
New +$97
NAVB
953
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$0 ﹤0.01%
+100
New +$86
WPG
954
DELISTED
Washington Prime Group Inc.
WPG
$0 ﹤0.01%
+15
New +$544

Similar funds

tru Independence's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for tru Independence, which disclosed 959 positions worth $695M. Its ten largest holdings account for 23% of the portfolio.

Its largest position is Bristol-Myers Squibb: 1,081,698 shares worth $49.3M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, followed by Technology and Industrials.

  • tru Independence's largest Q4 2019 buy was Bristol-Myers Squibb: 1,081,698 shares worth $49.3M.
  • tru Independence's ten largest holdings make up 23% of its $695M portfolio in Q4 2019.
  • tru Independence disclosed 959 positions in Q4 2019, its first 13F filing on record.

Based on tru Independence's 13F filing for Q4 2019, filed 19 May 2020.